IRON Quote, Financials, Valuation and Earnings

Emergent BioSolutions, Inc. has a net margin of -- compared to Disc Medicine, Inc.'s net margin of 22.16%. Disc Medicine, Inc.'s return on equity of -32.82% beat Emergent BioSolutions, Inc.'s return on equity of 14.25%.

Disc Medicine, Inc. has a consensus price target of $103.42, signalling upside risk potential of 68.54%. On the other hand Emergent BioSolutions, Inc. has an analysts' consensus of $13.50 which suggests that it could grow by 23.51%. Given that Disc Medicine, Inc. has higher upside potential than Emergent BioSolutions, Inc., analysts believe Disc Medicine, Inc. is more attractive than Emergent BioSolutions, Inc..

Disc Medicine, Inc. has a beta of 0.885, which suggesting that the stock is 11.549% less volatile than S&P 500. In comparison Emergent BioSolutions, Inc. has a beta of 2.346, suggesting its more volatile than the S&P 500 by 134.572%.

Disc Medicine, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Emergent BioSolutions, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Disc Medicine, Inc. pays -- of its earnings as a dividend. Emergent BioSolutions, Inc. pays out -- of its earnings as a dividend.

Disc Medicine, Inc. quarterly revenues are --, which are smaller than Emergent BioSolutions, Inc. quarterly revenues of $231.1M. Disc Medicine, Inc.'s net income of -$62.3M is lower than Emergent BioSolutions, Inc.'s net income of $51.2M. Notably, Disc Medicine, Inc.'s price-to-earnings ratio is -- while Emergent BioSolutions, Inc.'s PE ratio is 8.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Disc Medicine, Inc. is -- versus 0.77x for Emergent BioSolutions, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -- compared to Disc Medicine, Inc.'s net margin of 34.4%. Disc Medicine, Inc.'s return on equity of -32.82% beat Eli Lilly & Co.'s return on equity of 104.39%.

Disc Medicine, Inc. has a consensus price target of $103.42, signalling upside risk potential of 68.54%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,211.21 which suggests that it could grow by 19.98%. Given that Disc Medicine, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Disc Medicine, Inc. is more attractive than Eli Lilly & Co..

Disc Medicine, Inc. has a beta of 0.885, which suggesting that the stock is 11.549% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.388, suggesting its less volatile than the S&P 500 by 61.171%.

Disc Medicine, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.62% to investors and pays a quarterly dividend of $1.73 per share. Disc Medicine, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Disc Medicine, Inc. quarterly revenues are --, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Disc Medicine, Inc.'s net income of -$62.3M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Disc Medicine, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 44.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Disc Medicine, Inc. is -- versus 14.11x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Masimo Corp. has a net margin of -- compared to Disc Medicine, Inc.'s net margin of 14.46%. Disc Medicine, Inc.'s return on equity of -32.82% beat Masimo Corp.'s return on equity of -19.18%.

Disc Medicine, Inc. has a consensus price target of $103.42, signalling upside risk potential of 68.54%. On the other hand Masimo Corp. has an analysts' consensus of $178.60 which suggests that it could grow by 2%. Given that Disc Medicine, Inc. has higher upside potential than Masimo Corp., analysts believe Disc Medicine, Inc. is more attractive than Masimo Corp..

Disc Medicine, Inc. has a beta of 0.885, which suggesting that the stock is 11.549% less volatile than S&P 500. In comparison Masimo Corp. has a beta of 1.262, suggesting its more volatile than the S&P 500 by 26.165%.

Disc Medicine, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Disc Medicine, Inc. pays -- of its earnings as a dividend. Masimo Corp. pays out -- of its earnings as a dividend.

Disc Medicine, Inc. quarterly revenues are --, which are smaller than Masimo Corp. quarterly revenues of $371.5M. Disc Medicine, Inc.'s net income of -$62.3M is lower than Masimo Corp.'s net income of $53.7M. Notably, Disc Medicine, Inc.'s price-to-earnings ratio is -- while Masimo Corp.'s PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Disc Medicine, Inc. is -- versus 5.53x for Masimo Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Penumbra, Inc. has a net margin of -- compared to Disc Medicine, Inc.'s net margin of 12.93%. Disc Medicine, Inc.'s return on equity of -32.82% beat Penumbra, Inc.'s return on equity of 13.4%.

Disc Medicine, Inc. has a consensus price target of $103.42, signalling upside risk potential of 68.54%. On the other hand Penumbra, Inc. has an analysts' consensus of $348.53 which suggests that it could grow by 2.7%. Given that Disc Medicine, Inc. has higher upside potential than Penumbra, Inc., analysts believe Disc Medicine, Inc. is more attractive than Penumbra, Inc..

Disc Medicine, Inc. has a beta of 0.885, which suggesting that the stock is 11.549% less volatile than S&P 500. In comparison Penumbra, Inc. has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.405%.

Disc Medicine, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Penumbra, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Disc Medicine, Inc. pays -- of its earnings as a dividend. Penumbra, Inc. pays out -- of its earnings as a dividend.

Disc Medicine, Inc. quarterly revenues are --, which are smaller than Penumbra, Inc. quarterly revenues of $354.7M. Disc Medicine, Inc.'s net income of -$62.3M is lower than Penumbra, Inc.'s net income of $45.9M. Notably, Disc Medicine, Inc.'s price-to-earnings ratio is -- while Penumbra, Inc.'s PE ratio is 81.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Disc Medicine, Inc. is -- versus 9.97x for Penumbra, Inc.. Usually stocks with elevated PS ratios are considered overvalued.